← Back to patent-cliff list
Remibrutinib
Tier C — Watch / tradeRemibrutinib
Novartis
Originator
2025
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：BTK
Brand：Rhapsido
Indications (approved)：Chronic urticaria, Urticaria
Regional status
US
Approved
2025-09-30
EU
Approved
2026-04-23
China
Approved
2025-11-25
Japan
Approved
2026-09-04
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Remibrutinib?
Approved indications include: Chronic urticaria, Urticaria.
When does the Remibrutinib patent expire?
No public expiry year is available for Remibrutinib yet; this page updates once verified.
How do I get a quote for Remibrutinib intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-01